Summary
41.87 -0.75(-1.75%)05/17/2024
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.46 | -1.36 | -16.33 | -6.28 | 10.19 | -10.82 | 31.55 | 79.32 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 41.96 | |
| Open | 43.21 | |
| High | 43.32 | |
| Low | 41.48 | |
| Volume | 657,737 | |
| Change | -1.06 | |
| Change % | -2.46 | |
| Avg Volume (20 Days) | 637,290 | |
| Volume/Avg Volume (20 Days) Ratio | 1.03 | |
| 52 Week Range | 31.52 - 54.98 | |
| Price vs 52 Week High | -23.68% | |
| Price vs 52 Week Low | 33.12% | |
| Range | -2.89 | |
| Gap Up/Down | 0.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,481 | |
| EBIDTA | -380,151,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.2400 | |
| WallStreet Target Price | 142.00 | |
| Book Value | 13.7380 | |
| Earnings Per Share | -5.3210 | |
| EPS Estimate Current Quarter | -1.4100 | |
| EPS Estimate Next Quarter | -1.5000 | |
| EPS Estimate Current Year | -6.2900 | |
| EPS Estimate Next Year | -5.7100 | |
| Diluted EPS (TTM) | -5.3210 | |
| Revenues | ||
| Profit Marging | -0.9889 | |
| Operating Marging (TTM) | -1.0437 | |
| Return on asset (TTM) | -0.1704 | |
| Return on equity (TTM) | -0.4445 | |
| Revenue TTM | 359,559,008 | |
| Revenue per share TTM | 5.3810 | |
| Quarterly Revenue Growth (YOY) | 0.0020 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -147,183,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.6870 | |
| Revenue Enterprise Value | 12.8401 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 68,162,200 | |
| Shares Float | 64,730,939 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.49 | |
| Institutions (%) | 99.62 | |
05/17 16:30 EST - globenewswire.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 17,180 restricted stock units of the company's common stock to ten newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 17,180 restricted stock units of the company's common stock to ten newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
05/07 16:30 EST - globenewswire.com
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America's 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America's 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.
05/03 13:26 EST - zacks.com
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
05/02 21:01 EST - zacks.com
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/02 20:28 EST - seekingalpha.com
Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Anupam Rama – JPMorgan Tazeen Ahmad - Bank of America Securities Gena Wang – Barclays Dae Gon Ha – Stifel Kristen Kluska - Cantor Fitzgerald Maurice Raycroft – Jefferies Jeffery Hung - Morgan Stanley Joon Lee - Truist Joseph Schwartz - Leerink Partners Brendan Smith - TD Cowen Lidia Rachkova - Goldman Sachs Jack Allen – Baird Luca Issi - RBC Capital Operator Good afternoon, and welcome to the Ultragenyx First Quarter 2024 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.
Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Anupam Rama – JPMorgan Tazeen Ahmad - Bank of America Securities Gena Wang – Barclays Dae Gon Ha – Stifel Kristen Kluska - Cantor Fitzgerald Maurice Raycroft – Jefferies Jeffery Hung - Morgan Stanley Joon Lee - Truist Joseph Schwartz - Leerink Partners Brendan Smith - TD Cowen Lidia Rachkova - Goldman Sachs Jack Allen – Baird Luca Issi - RBC Capital Operator Good afternoon, and welcome to the Ultragenyx First Quarter 2024 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.
05/02 18:11 EST - zacks.com
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $2.33 per share a year ago.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $2.33 per share a year ago.
05/02 16:00 EST - globenewswire.com
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million
04/30 16:00 EST - globenewswire.com
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company's efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with.
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company's efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with.
04/25 16:30 EST - globenewswire.com
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
04/16 12:35 EST - zacks.com
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
04/12 16:22 EST - globenewswire.com
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.
04/12 08:00 EST - globenewswire.com
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome
02/27 16:30 EST - GlobeNewsWire
Ultragenyx to Participate at Investor Conferences in March
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
Ultragenyx to Participate at Investor Conferences in March
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
02/16 08:56 EST - zacks.com
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
02/15 23:55 EST - seekingalpha.com
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
02/15 19:01 EST - zacks.com
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/15 18:11 EST - zacks.com
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compares to loss of $2.16 per share a year ago.
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compares to loss of $2.16 per share a year ago.